Skip to main content

Table 1 Baseline demographics, apolipoprotein E status and cerebrospinal fluid markers in the cross-sectional population by baseline status

From: Comparison of CSF markers and semi-quantitative amyloid PET in Alzheimer’s disease diagnosis and in cognitive impairment prognosis using the ADNI-2 database

Baseline status Control subjects (n = 157) SMC/MCI (n = 396) AD (n = 124)
Male sex 77 (49%) 204 (52%) 72 (58%)
Age, years 74 ± 6 72 ± 7a 75 ± 8
ApoE4 carriers 42 (27%) 186 (47%)b 82 (66%)c
Baseline cognition
 GDS 0.7 ± 1.1 1.4 ± 1.4b 1.7 ± 14c
 MMSE 29 ± 1 27 ± 3b 23 ± 2c
 CDR 0 157 (100%) 96 (24%)b 0c
 CDR 0.5 0 299 (76%)a 53 (43%)c
 CDR ≥1 0 1 (0.3%) 71 (57%)c
 ADAS-cog 9 ± 5 16 ± 10b 31 ± 8c
Baseline CSF
 Aβ1–42, ng/L 196 ± 50 175 ± 53b 137 ± 38c
 Tau, ng/L 67 ± 34 88 ± 54b 133 ± 65c
 p-Tau181, ng/L 33 ± 16 43 ± 26b 60 ± 35c
 p-Tau181/Aβ1–42 0.19 ± 0.13 0.29 ± 0.24b 0.48 ± 0.32c
  1. Abbreviations: Aβ Amyloid-β1–42, AD Alzheimer’s disease, ADAS-cog Alzheimer’s Disease Assessment Scale–Cognitive Subscale, ApoE Apolipoprotein E, CDR Clinical Dementia Rating, GDS Geriatric Depression Scale, MCI Mild cognitive impairment, MMSE Mini Mental State Examination, p-tau Phosphorylated tau, SMC Significant memory complaint
  2. a p < 0.01 vs control subjects
  3. b p < 0.001 vs control subjects
  4. c p < 0.001 vs patients with SMC/MCI